Novakand Pharma AB (publ) (STO:NOVKAN)

Market Cap	3.03M -97.9%
Revenue (ttm)	n/a
Net Income	-47.23M
EPS	-0.39
Shares Out	121.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,061,648
Open	0.0499
Previous Close	0.0446
Day's Range	0.0223 - 0.0499
52-Week Range	0.0223 - 2.2500
Beta	1.19
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 24, 2026

About Novakand Pharma AB

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in Septembe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NOVKAN

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Apr 15, 2026

Data Sources Report a data error